Buspirone as a Candidate Medication for Methamphetamine Abuse

Status Completed

Clinical Trial Summary

Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01843205
Study type	Interventional
Source	University of Kentucky
Contact
Status	Completed
Phase	Phase 1
Start date	April 2013
Completion date	March 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01813656` - An Study of Aripiprazole in the Treatment of Methamphetamine Dependence	Phase 4
Completed	`NCT00984360` - Study of Naltrexone for Methamphetamine Addiction	Phase 2
Completed	`NCT01685463` - Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving	N/A
Completed	`NCT00569374` - Safety and Tolerability of Modafinil for Methamphetamine Dependence	Phase 2
Completed	`NCT01967381` - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse	Early Phase 1
Completed	`NCT01354470` - A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence	Phase 2
Active, not recruiting	`NCT01044238` - Methylphenidate to Treat Methamphetamine Dependence	Phase 2
Terminated	`NCT01019707` - Safety Assessment of Atomoxetine With MA IV Administration	Phase 1
Completed	`NCT01215929` - Studying Amphetamine Withdrawal in Humans	Phase 2
Completed	`NCT00227123` - A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence	N/A
Recruiting	`NCT02568878` - Creatine for Depressed Male and Female Methamphetamine Users	Phase 3
Completed	`NCT01011829` - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	Phase 2
Completed	`NCT01007539` - Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence	Phase 3
Completed	`NCT01062451` - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence	Phase 1
Completed	`NCT00687713` - Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence	Phase 2
Completed	`NCT01063205` - NAC as a Potential Treatment for Methamphetamine Dependence	Phase 1
Completed	`NCT02058966` - Pilot Study of Entacapone for Methamphetamine Abuse	Early Phase 1
Completed	`NCT00332605` - N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence	Phase 2
Completed	`NCT01860807` - Trial of Ibudilast for Methamphetamine Dependence	Phase 2
Terminated	`NCT01813643` - A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis	Phase 4